{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T04:37:31Z","timestamp":1760243851128,"version":"build-2065373602"},"reference-count":10,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:00:00Z","timestamp":1760140800000},"content-version":"vor","delay-in-days":375,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Med"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.medj.2024.08.005","type":"journal-article","created":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T10:35:37Z","timestamp":1728642937000},"page":"1197-1199","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Expanding the frontiers of therapeutic options in hidradenitis suppurativa: The valid contribution of bimekizumab"],"prefix":"10.1016","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7939-0026","authenticated-orcid":false,"given":"Elisa","family":"Molinelli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edoardo","family":"De Simoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oriana","family":"Simonetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.medj.2024.08.005_bib1","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1016\/S0140-6736(24)00101-6","article-title":"Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials","volume":"403","author":"Kimball","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.medj.2024.08.005_bib2","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/jdv.16677","article-title":"Hidradenitis suppurativa: an update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life","volume":"35","author":"Nguyen","year":"2021","journal-title":"J.\u00a0Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.medj.2024.08.005_bib3","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1111\/bjd.19337","article-title":"Efficacy and safety of topical resorcinol 15% as long-term treatment of mild-to-moderate hidradenitis suppurativa: a valid alternative to clindamycin in the panorama of antibiotic resistance","volume":"183","author":"Molinelli","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.medj.2024.08.005_bib4","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1093\/ced\/llad229","article-title":"Bimekizumab in hidradenitis suppurativa: a valid and effective emerging treatment","volume":"48","author":"Molinelli","year":"2023","journal-title":"Clin. Exp. Dermatol."},{"key":"10.1016\/j.medj.2024.08.005_bib5","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1080\/1744666X.2023.2298356","article-title":"Biologics for Hidradenitis suppurativa: evolution of the treatment paradigm","volume":"20","author":"Maronese","year":"2024","journal-title":"Expert Rev. Clin. Immunol."},{"key":"10.1016\/j.medj.2024.08.005_bib6","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41392-023-01620-3","article-title":"The IL-17 family in diseases: from bench to bedside","volume":"8","author":"Huangfu","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.medj.2024.08.005_bib7","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/bjd\/ljad345","article-title":"Hidradenitis suppurativa: new insights into disease mechanisms and an evolving treatment landscape","volume":"190","author":"Krueger","year":"2024","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.medj.2024.08.005_bib8","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1016\/S0140-6736(24)00591-9","article-title":"Bimekizumab: dual inhibition as a promising tool in the management of hidradenitis suppurativa","volume":"403","author":"Molinelli","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.medj.2024.08.005_bib9","doi-asserted-by":"crossref","DOI":"10.1111\/exd.14964","article-title":"Physiological roles of human interleukin-17 family","volume":"33","author":"Liu","year":"2024","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.medj.2024.08.005_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000539264","article-title":"Guidelines How to Integrate Surgery and Targeted Therapy with Biologics for the Treatment of Hidradenitis Suppurativa: Delphi Consensus Statements from an Italian Expert Panel","author":"Offidani","year":"2024","journal-title":"Dermatology"}],"container-title":["Med"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634024003362?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634024003362?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T21:58:25Z","timestamp":1760219905000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666634024003362"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":10,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S2666634024003362"],"URL":"https:\/\/doi.org\/10.1016\/j.medj.2024.08.005","relation":{},"ISSN":["2666-6340"],"issn-type":[{"type":"print","value":"2666-6340"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Expanding the frontiers of therapeutic options in hidradenitis suppurativa: The valid contribution of bimekizumab","name":"articletitle","label":"Article Title"},{"value":"Med","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medj.2024.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}